133MPA [medroxyprogesterone] revisited: A phase II study of anti-metastatic, anti-angiogenic therapy in postmenopausal patients with hormone receptor negative breast cancer. A Translational Breast Cancer Research Consortium (TBCRC) trial.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Medroxyprogesterone; Methotrexate
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TBCRC
- 03 Oct 2014 Biomarkers information updated
- 28 Mar 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 28 Mar 2013 Planned End Date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.